title: CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
abstract: OBJECTIVE
  We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a chemotherapy regimen specifically devised for elderly patients, ie, etoposide, mitoxantrone, and prednimustine (VMP), versus the standard regimen of cyclophosphamide, doxorobucin, vincristine, and prednisone (CHOP) in patients older than 70 years of age with intermediate- and high-grade non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  Patients older than 70 years of age with stage II, III, or IV intermediate- and high-grade NHL, with an Eastern Cooperative Oncology Group (ECOG) performance status less than 4 and acceptable cardiac, renal, and liver function were randomized to receive six courses of VMP or six courses of CHOP. Between February 1989 and June 1994, 130 patients aged 70 to 93 years (median, 75) were enrolled and 120 were assessable for response, 60 patients in each arm.
  
  
  RESULTS
  Overall objective response rates were 50% and 77% in VMP- and CHOP-treated patients, respectively (P = .01), while complete response (CR) rates were borderline significant (27% v 45%; P = .06). At 2 years, the progression-free survival (PFS) rate was 25% with VMP versus 55% with CHOP (P = .002) and the overall survival (OS) rate was 30% with VMP versus 65% with CHOP (P = .004). Statistically significant more alopecia and neurologic and gastrointestinal toxicities were reported with CHOP.
  
  
  CONCLUSIONS
  CHOP is the standard regimen for patients > or = 70 years of age with stage II to IV intermediate- and high-grade NHL.
authors.affiliation: Division of Medical Oncology and AIDS, Aviano Cancer Center, Italy. oma@ets.it
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: D
authors.initials: D
authors.lastname: Errante
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: I
authors.initials: I
authors.lastname: Teodorovic
authors.forename: J C
authors.initials: JC
authors.lastname: Kluin-Nelemans
authors.forename: J
authors.initials: J
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: Bron
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: R
authors.initials: R
authors.lastname: Somers
authors.forename: V
authors.initials: V
authors.lastname: Zagonel
authors.forename: E M
authors.initials: EM
authors.lastname: Noordijk
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008942:Mitoxantrone / Q000008:administration & dosage; D011238:Prednimustine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D008942:Mitoxantrone; D011241:Prednisone